



10563045 - GAU: 1644

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on September 21, 2006

Frank C. Eisenschek

Frank C. Eisenschek, Ph.D., Patent Attorney

INFORMATION DISCLOSURE
STATEMENT

Examining Group 1646
Patent Application
Docket No. INN-133
Serial No. 10/563,045

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646
Applicants : Alessandro Moretta, Mariella Della Chiesa
Serial No. : 10/563,045
Filed : December 30, 2005
Conf. No. : 6062
For : PAN-KIR2DL NK-Receptor Antibodies and Their Use in Diagnostik and Therapy

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:


The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 U.S.C. § 371. Applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notice of Acceptance of the Application Under 35 USC 371 (Form PCT/DO/EO/903). The Notice does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. However, Applicants have not submitted copies of the U.S. patents cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. 1.98(a)(2)(ii). In accordance with 37 C.F.R. § 1.56, Applicants hereby request that the references cited in the International Search

Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicants have also listed on form PTO/SB/08 numerous references which have not been cited in the International Search Report. Copies of these documents are enclosed with this Information Disclosure Statement. Applicants respectfully request that these references be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/si

Attachments: Form PTO/SB/08; copies of cited references.



10563045 - GAU: 1644

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

3

Application Number	10/563,045
Filing Date	December 30, 2005
First Named Inventor	Alessandro Moretta
Art Unit	1646
Examiner Name	
Attorney Docket Number	INN-133

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-6,524,583	02-25-2003	THORPE <i>et al.</i>	All
	U2	US-5,650,491	07-22-1997	REED <i>et al.</i>	All
	U3	US-5,539,094	07-23-1996	REED <i>et al.</i>	All
	U4	US-5,660,827	08-26-1997	THORPE <i>et al.</i>	All
	U5	US-4,816,567	03-28-1989	CABILLY <i>et al.</i>	All
	U6	US-5,583,034	12-10-1996	GREEN <i>et al.</i>	All
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 98/16551 A2	04-23-1998	GENENTECH, INC.	All	
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/563,045
Filing Date	December 30, 2005
First Named Inventor	Alessandro Moretta
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	INN-133

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BARTEN, R. <i>et al.</i> "Divergent and convergent evolution of NK-cell receptors", <i>TRENDS in Immunology</i> , January 2001, pp. 52-57, Vol. 22, No. 1.	
	R2	BIASSONI, R. <i>et al.</i> "Human CD3 ⁺ CD16 ⁺ Natural Killer Cells Express the hGATA-3 T Cell Transcription Factor and an Unrearranged 2.3-kb TcR δ Transcript", <i>Eur. J. Immunol.</i> , 1993, pp. 1083-1087, Vol. 23.	
	R3	BOYINGTON, J. C. <i>et al.</i> "Crystal Structure of an NK Cell Immunoglobulin-like Receptor in Complex with its Class I MHC Ligand", <i>Nature</i> , June 1, 2000, pp. 537-543, Vol. 405.	
	R4	FAN, Q. R. <i>et al.</i> "Crystal Structure of the Human Natural Killer Cell Inhibitory Receptor KIR2DL1-HLA-Cw4 Complex", <i>Nature Immunology</i> , May 2001, pp. 452-460, Vol. 2, No. 5.	
	R5	FARAG, S. S. <i>et al.</i> "Natural Killer Cell Receptors: New Biology and Insights into the Graft-Versus-Leukemia Effect", <i>BLOOD</i> , September 15, 2002, pp. 1935-1947, Vol. 100, No. 6.	
	R6	GAUTHIER, L. <i>et al.</i> "u-Surrogate Light Chain Physicochemical Interactions of the Human PreB Cell Receptor: Implications for V _H Repertoire Selection and Cell Signaling at the PreB Cell Stage", <i>The Journal of Immunology</i> , 1999, pp. 41-50, Vol. 162.	
	R7	KOH, C. Y. <i>et al.</i> "NK Inhibitory-Receptor Blockade for Purging of Leukemia: Effects on Hematopoietic Reconstitution", <i>Biology of Blood and Marrow Transplantation</i> , 2002, pp. 17-25, Vol. 8.	
	R8	MAENAKA, K. <i>et al.</i> "Crystal Structure of the Human p58 Killer Cell Inhibitory Receptor (KIR2DL3) Specific for HLA-Cw3-Related MHC Class I", <i>Structure</i> , April 1999, pp. 391-398, Vol. 7, No. 4.	
	R9	MORETTA, A. <i>et al.</i> "Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytotoxicity", <i>Annu. Rev. Immunol.</i> , 2001, pp. 197-223 and Table of Contents, Vol. 19.	
	R10	MORETTA, A. <i>et al.</i> "Identification of Four Subsets of Human CD3 ⁺ CD16 ⁺ Natural Killer (NK) Cells by the Expression of Clonally Distributed Functional Surface Molecules: Correlation between Subset Assignment of NK Clones and Ability to Mediate Specific Alloantigen Recognition", <i>J. Exp. Med.</i> , December 1990, pp. 1589-1598, Vol. 172.	
	R11	MORETTA, A. <i>et al.</i> "A Novel Surface Antigen Expressed by a Subset of Human CD3 ⁺ CD16 ⁺ Natural Killer Cells", <i>The Journal of Experimental Medicine</i> , March 1990, pp. 695-714, Vol. 171.	
	R12	MORETTA, A. <i>et al.</i> "P58 Molecules as Putative Receptors for Major Histocompatibility Complex (MHC) Class I Molecules in Human Natural Killer (NK) Cells. Anti-p58 Antibodies Reconstitute Lysis of MHC Class I-protected Cells in NK Clones Displaying Different Specificities", <i>J. Exp. Med.</i> , August 1993, pp. 597-604, Vol. 178.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/563,045
Filing Date	December 30, 2005
First Named Inventor	Alessandro Moretta
Group Art Unit	1646
Examiner Name	/Marianne DiBrino/
Attorney Docket Number	INN-133

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R13	MORETTA, A. <i>et al.</i> "Receptors for HLA Class-I Molecules in Human Natural Killer Cells", <i>Annu. Rev. Immunol.</i> , 1996, pp. 619-648, Vol. 14.	
	R14	PENDE, D. <i>et al.</i> "Identification and Molecular Characterization of NKP30, a Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells", <i>J. Exp. Med.</i> , November 15, 1999, pp. 1505-1516, Vol. 190, No. 10.	
	R15	RUGGERI, L. <i>et al.</i> "Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants", <i>Science</i> , March 15, 2002, pp. 2097-2100, Vol. 295.	
	R16	SAUNAL, H. <i>et al.</i> "Mapping of Viral Conformational Epitopes Using Biosensor Measurements", <i>Journal of Immunological Methods</i> , 1995, pp. 33-41, Vol. 183.	
	R17	SAULQUIN, X. <i>et al.</i> "Crystal Structure of the Human Natural Killer Cell Activating Receptor KIR2DS2 (CD158j)", <i>J. Exp. Med.</i> , April 7, 2003, pp. 933-938, Vol. 197, No. 7.	
	R18	SHIN, J.-S. <i>et al.</i> "Monoclonal Antibodies with Various Reactivity to p58 Killer Inhibitory Receptors", <i>Hybridoma</i> , 1999, pp. 521-527, Vol. 18, No. 6.	
	R19	SPAGGIARI, G. M. <i>et al.</i> "Soluble HLA Class I Induces NK Cell Apoptosis Upon the Engagement of Killer-Activating HLA Class I Receptors through FasL-Fas Interaction", <i>BLOOD</i> , December 1, 2002, pp. 4098-4107, Vol. 100, No. 12.	
	R20	WAGTMANN, N. <i>et al.</i> "Killer Cell Inhibitory Receptors Specific for HLA-C and HLA-B Identified by Direct Binding and by Functional Transfer", <i>Immunity</i> , December 1995, pp. 801-809, Vol. 3.	
	R21	WAGTMANN, N. <i>et al.</i> "Molecular Clones of the p58 NK Cell Receptor Reveal Immunoglobulin-Related Molecules with Diversity in Both the Extra- and Intracellular Domains", <i>Immunity</i> , May 1995, pp. 439-449, Vol. 2.	
	R22	WARREN, H.S. <i>et al.</i> "Functional analysis of CD158b monoclonal antibodies recognizing the killer Ig-like receptors KIR2DS2, KIR2DL2 and KIR2DL3", <i>Tissue Antigens</i> , 2000, pp. 80-81, Vol. 55, No. Supplement 15, XP009040899 (abstract only).	
	R23		
	R24		

Examiner Signature	/Marianne DiBrino/	Date Considered	06/14/06
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./